Fionan Donohoe1, Mary Higgins1,2, Shane Higgins1, Fionnuala McAuliffe1,2, Karen Murphy3. 1. Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Republic of Ireland. 2. UCD Obstetrics and Gynaecology, School of Medicine and Medical Science, National Maternity Hospital, Dublin, Republic of Ireland. 3. Department of Haematology, St Vincent's University Hospital, Dublin, Republic of Ireland.
Abstract
BACKGROUND: Rituximab is a novel second-line agent for the treatment of immune thrombocytopenic purpura. Minimal data exist on the use of rituximab in pregnancy. This case illustrates the successful treatment of severe immune thrombocytopenic purpura diagnosed in pregnancy, refractory to all other medical management. CASE: A 32-year-old nulliparous woman was diagnosed with severe immune thrombocytopenic purpura at the time of booking for antenatal care (platelet level of 13 × 109/L). Standard treatment failed to adequately increase her platelet count. Therapy with rituximab was instituted, and her platelet count rose to normal levels, without side effects, and remained at a normal level throughout the pregnancy. There were no maternal or neonatal ill-effects of rituximab therapy. CONCLUSION: Rituximab is potentially a safe treatment option for the management of immune thrombocytopenic purpura in pregnancy with good maternal and neonatal outcome when conventional treatments have been unsuccessful. Research is limited to case reports, and therefore limited information currently exists to guide clinicians.
BACKGROUND: Rituximab is a novel second-line agent for the treatment of immune thrombocytopenic purpura. Minimal data exist on the use of rituximab in pregnancy. This case illustrates the successful treatment of severe immune thrombocytopenic purpura diagnosed in pregnancy, refractory to all other medical management. CASE: A 32-year-old nulliparous woman was diagnosed with severe immune thrombocytopenic purpura at the time of booking for antenatal care (platelet level of 13 × 109/L). Standard treatment failed to adequately increase her platelet count. Therapy with rituximab was instituted, and her platelet count rose to normal levels, without side effects, and remained at a normal level throughout the pregnancy. There were no maternal or neonatal ill-effects of rituximab therapy. CONCLUSION: Rituximab is potentially a safe treatment option for the management of immune thrombocytopenic purpura in pregnancy with good maternal and neonatal outcome when conventional treatments have been unsuccessful. Research is limited to case reports, and therefore limited information currently exists to guide clinicians.
Authors: D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy Journal: Blood Date: 1997-09-15 Impact factor: 22.113
Authors: J N George; S H Woolf; G E Raskob; J S Wasser; L M Aledort; P J Ballem; V S Blanchette; J B Bussel; D B Cines; J G Kelton; A E Lichtin; R McMillan; J A Okerbloom; D H Regan; I Warrier Journal: Blood Date: 1996-07-01 Impact factor: 22.113
Authors: Shirish R Sangle; Pamela M K Lutalo; Rachel J Davies; Munther A Khamashta; David P D'Cruz Journal: J Autoimmun Date: 2013-04-19 Impact factor: 7.094
Authors: M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson Journal: Blood Date: 1994-01-15 Impact factor: 22.113
Authors: Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter Journal: Blood Date: 2009-10-21 Impact factor: 22.113